President Donald Trump, along with other high tariffs, have said that pharma tariffs would start small but could balloon to nearly 250%  in an attempt to move drug manufacturing to the U.S. These tariffs could affect how patients afford their prescriptions and could threaten abilities to fund research into new medicines. International Trade Attorney Michelle Schulz has been monitoring these developments and goes into detail how this blunt attack on pharmaceuticals could be bad for everyone.